Teva Pharmaceutical Industries (NYSE:TEVA) Updates Q1 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its first quarter 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.520-0.520 for the period, compared to the consensus earnings per share estimate of 0.480. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion. Teva Pharmaceutical Industries also updated its FY 2025 guidance to 2.350-2.650 EPS.

Wall Street Analysts Forecast Growth

Several analysts have commented on TEVA shares. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Down 2.8 %

Shares of Teva Pharmaceutical Industries stock opened at $15.06 on Friday. Teva Pharmaceutical Industries has a 1 year low of $12.51 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business has a 50 day moving average price of $17.21 and a 200 day moving average price of $18.12. The company has a market capitalization of $17.07 billion, a P/E ratio of -10.38, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.